Stock Scorecard



Stock Summary for Praxis Precision Medicines Inc (PRAX) - $38.66 as of 3/28/2025 8:46:43 PM EST

Total Score

10 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PRAX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PRAX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PRAX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PRAX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PRAX (40 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PRAX

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Praxis Precision Medicine ( NASDAQ:PRAX ) 3/24/2025 12:00:00 PM
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting 3/24/2025 12:00:00 PM
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 3/4/2025 10:00:00 PM
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Praxis Precision Medicine ( NASDAQ:PRAX ) 3/4/2025 10:00:00 PM
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Praxis Precision Medicine ( NASDAQ:PRAX ) 3/3/2025 6:26:00 PM
Market Whales and Their Recent Bets on PRAX Options - Praxis Precision Medicine ( NASDAQ:PRAX ) 2/28/2025 7:45:00 PM
Praxis Precision Medicines, Inc. ( PRAX ) Reports Q4 Loss, Tops Revenue Estimates 2/28/2025 2:10:00 PM
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update 2/28/2025 1:00:00 PM
IGM Biosciences, Inc. ( IGMS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release 2/27/2025 3:00:00 PM
Praxis Precision Medicines, Inc. ( PRAX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release 2/25/2025 3:00:00 PM

Financial Details for PRAX

Company Overview

Ticker PRAX
Company Name Praxis Precision Medicines Inc
Country USA
Description Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/12/2025

Stock Price History

Last Day Price 38.66
Price 4 Years Ago 295.50
Last Day Price Updated 3/28/2025 8:46:43 PM EST
Last Day Volume 414,831
Average Daily Volume 595,883
52-Week High 91.83
52-Week Low 30.01
Last Price to 52 Week Low 28.82%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -29.03
Free Cash Flow Ratio 1.90
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 10.96
Total Cash Per Share 20.39
Book Value Per Share Most Recent Quarter 22.93
Price to Book Ratio 1.73
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 90.03
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 20,163,200
Market Capitalization 779,509,312
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 42.39%
Reported EPS 12 Trailing Months -10.87
Reported EPS Past Year -10.27
Reported EPS Prior Year -4.35
Net Income Twelve Trailing Months -151,018,000
Net Income Past Year -123,300,000
Net Income Prior Year -214,029,000
Quarterly Revenue Growth YOY 1,349.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -857.00%

Balance Sheet

Total Cash Most Recent Quarter 411,200,000
Total Cash Past Year 81,300,000
Total Cash Prior Year 100,489,000
Net Cash Position Most Recent Quarter 411,200,000
Net Cash Position Past Year 81,300,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 69,669,000
Total Stockholder Equity Prior Year 76,106,000
Total Stockholder Equity Most Recent Quarter 382,666,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -99,546,000
Free Cash Flow Per Share Twelve Trailing Months -4.94
Free Cash Flow Past Year -111,186,000
Free Cash Flow Prior Year -185,487,000

Options

Put/Call Ratio 1.87
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -6.75
MACD Signal -8.23
20-Day Bollinger Lower Band 31.86
20-Day Bollinger Middle Band 66.58
20-Day Bollinger Upper Band 101.30
Beta 2.77
RSI 37.41
50-Day SMA 59.47
150-Day SMA 43.26
200-Day SMA 94.51

System

Modified 3/28/2025 5:10:27 AM EST